Eli Lilly Benelux is part of Eli Lilly and Company, a world-wide biopharmaceutical company specializing in innovative research into new molecules of biological and pharmaceutical origin. Being one of the world leaders in the health sector with 42.000 employees on global level, Eli Lilly focuses on five specific therapeutic domains: oncology, metabolic diseases (diabetes and growth disorders), neurodegeneration, immunology and pain. The Eli Lilly brand stands for integrity, excellence and respect, and the company’s greatest contribution to society is discovering medicines that help people live longer, healthier, and more active lives. These values have been leading the company over the last 140 years.
The company was founded in 1876 by Colonel Eli Lilly, who was committed to developing quality drugs that meet real needs. “His motto was to start with what you have and strive to make it better and better”, Frédéric Clais, Country Manager for Belgium, emphasises. “Whether it comes to the invention of new drugs and medical devices that help patients or the promotion of welfare within our communities, we remain faithful to that endeavour and we make every effort to improve patients’ lives”, he adds.Eli Lilly’s competitive advantages include superb quality products; highly skilled staff and continuous recruitment of the best employees; strong focus on customer satisfaction; and extensive investments in the development of new medication.
Aiming to accomplish their mission for improving people’s lives by developing treatments that meet those needs that are not yet fulfilled, Eli Lilly reinvests 25% of its sales is into research and development. “Our company’s vision is to improve global health in the 21st century, which is why 9.000 of our employees work in our R&D sector”, Frédéric Clais explains. “Investing in people and their development for is key for success”, he says. Belgium plays also an important role development of new medication. The company is collaborating with multiple hospitals and institutions. Last year, over 1.000 patients were included these clinical trials. “Belgium wants to maintain it leading positing in the implementation of Clinical Trials.Together with the Minister of Health, we are striving to keep this competitive advantage and maintain Belgium as a leading country in clinical investigation.”
Eli Lilly Benelux was founded in 1969 and currently employs 250 people on three sites: their commercial centre, their veterinary site and their centre for coordination of all clinical materials for clinical trials in Europe. “We do have a very open attitude for cooperation. We are looking for instance to welcome new partners with expertise in digitalisation, since this is becoming an increasing opportunity in healthcare”, the Country Manager points out.
“We believe it is our responsibility to do more. Globally, locally and personally, we devote our time, resources and expertise to advancing health and improving lives—all with the goal of making life better for people around the world. This is what makes working in the pharmaceutical industry so special. A passion I see every day within Eli Lilly Benelux”, Frédéric Clais concludes.